Degradation of HER2, EGFR may overcome drug resistance in HER2-positive breast cancers

VCU Massey–Sanford Burnham Prebys Drug Discovery Collaborative Program launches two projects

The VCU Massey Comprehensive Cancer Center completed the inaugural funding cycle of its VCU–Sanford Burnham Prebys Drug Discovery Collaborative Program, a collaboration with the Sanford Burnham Prebys Medical Discovery Institute in La Jolla, CA.

April 10, 2026

Vol.52 No.14

Clinical Roundup

Small molecule inhibitor blocks prostate cancer bone metastasis

Findings out of VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine, published in Pharmacological Research, show that a targeted small molecule inhibitor, IVMT-Rx-4, may prevent prostate tumors from spreading to an advanced and incurable stage in the bones.

April 03, 2026

Vol.52 No.13

Drugs & Targets

FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients

FDA has approved Ponlimsi (denosumab-adet) as a biosimilar to Prolia.

April 03, 2026

Vol.52 No.13

In Brief

Lisa Roth named director of pediatric hematology-oncology at Hassenfeld Children’s Hospital at NYU Langone

Lisa G. Roth was named director of the Division of Pediatric Hematology-Oncology at Hassenfeld Children’s Hospital at NYU Langone and Perlmutter Cancer Center. Roth is a pediatric oncologist, physician-scientist, and lymphoma survivor.

March 27, 2026

Vol.52 No.12

Clinical Roundup

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

March 27, 2026

Vol.52 No.12

Clinical Roundup

VCU Massey researchers lead international effort to produce multi-omic digital atlas of oral tissues

Researchers at VCU Massey Comprehensive Cancer Center led an international effort to create a multi-omic atlas of oral tissues with the aim of advancing the understanding of the immunoregulatory nature of human oral tissues. Recent analyses using data from this atlas suggest that fibroblasts may serve as the core regulators of structural immunity in the mouth.

March 27, 2026

Vol.52 No.12

Degradation of HER2, EGFR may overcome drug resistance in HER2-positive breast cancers

YOU MAY BE INTERESTED IN

VCU Massey–Sanford Burnham Prebys Drug Discovery Collaborative Program launches two projects

Small molecule inhibitor blocks prostate cancer bone metastasis

FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients

Lisa Roth named director of pediatric hematology-oncology at Hassenfeld Children’s Hospital at NYU Langone

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

VCU Massey researchers lead international effort to produce multi-omic digital atlas of oral tissues

Renew today!

Subscriber content

Never miss an issue!

Login